MEDTECH: Separating the wheat from the chaff

MedTech, which has historically been a defensive sector, has once again stood its ground even as broader markets have been rattled by the pandemic.

But, digging into the details throws up interesting trends: the resilience is underpinned by clear extremes.

Hence, leveraging the right opportunities assumes a greater importance and is critical to outperformance.

At the upcoming webinar, we will dissect these conflicting trends and share some interesting stock ideas that are best suited to win in a COVID-stricken world.

AlphaValue’s analysts on the sector, Sumit Sayal, Virendra Chauhan and Martin Schnee, Ph.D., just released a new strategy piece on European Medtech companies, including : BioMérieux, Qiagen, Sartorius Stedim, Sartorius, Getinge, and Siemens Healthineers.

Access to report : click here

Subscribe to our blog


Let’s talk
Interested in our research and want to learn more?
AlphaValue maintains its cautious stance when it comes to tariff friction costs on both sides of the po...
All of a sudden Telcos are as expensive as the broader market. This is news.
AlphaValue keeps on expressing its doubts about the direction of travel of the European car industry...